This invention relates to the application of PGG in the preparation of drugs for treating
acute leukemia, belonging to the field of
biomedical technology. To address the problems of narrow application range and easy development of
drug resistance in existing
acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating
acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and
colony formation of human acute
myeloid leukemia cells (MOLM-13) and human acute
lymphoblastic leukemia cells (Jurkat), and induce their
apoptosis. In animal models,
intraperitoneal injection of PGG can prolong the survival days of mice with acute
leukemia and reduce the infiltration of
leukemia cells in the liver,
spleen, and
bone marrow tissues. In this invention, PGG directly inhibits the viability of acute
leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific
gene mutations, resulting in a
lower risk of
drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.